Effect of cerebrotein hydrolysate-Ⅰon intestinal microflora regulation of mice with Parkinson’s disease

WU Xiao-Lin; LIU Ying-Juan; GE Ke-Li; REN Lei-Ming; GUO Yun-Liang; LI Hong-Yun

doi:10.16098/j.issn.0529-1356.2023.05.001

PDF(3818 KB)

Acta Anatomica Sinica ›› 2023, Vol. 54 ›› Issue (5) : 497-504. DOI: 10.16098/j.issn.0529-1356.2023.05.001

Neurobiology

Effect of cerebrotein hydrolysate-Ⅰon intestinal microflora regulation of mice with Parkinson’s disease

YAN Kun¹ WU Xiao-lin¹ LIU Ying-juan¹ GE Ke-li¹ REN Lei-ming² LI Hong-yun^3*

Author information +

History +

Abstract

Objective To investigate the neuroprotective effect and mechanism of cerebrotein hydrolysate-Ⅰ (CHⅠon1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced Parkinson’s disease (PD) mice. Methods Totally 36 healthy male C57BL/6 mice were randomly divided into control group(Ctrl), model group(MPTP) and CH-Ⅰ group. MPTP was used to induce PD model in mice, and CH-Ⅰ was injected intraperitoneally for intervention. The behavioral function of mice was detected by pole test, the expression of tyrosine hydroxylase (TH) was detected by immunohistochemistry, and the composition and diversity of intestinal microflora were detected by gene sequencing and bioinformatics analysis. Results Compared with the control group, MPTP induced behavioral deficits in PD mice after modeling (P<0.05), after CH-Ⅰ treatment, the behavioral defects of PD mice were improved compared with MPTP group (P<0.05). Immunohistochemical result showed that MPTP decreased the expression of the rate-limiting enzyme TH in dopamine synthesis, and increased the expression of TH after CH-Ⅰ treatment. The result of microbial diversity showed that the intestinal microflora diversity of mice decreased after MPTP treatment (P<0.05). At the “phylum” level, the number of Epsilonbacteraeota and Deferribacteres decreased sharply, while the number of Verrucomicrobia increased significantly. At the level of “family”, the number of Desulfovibrionaceae, Lachnospiraceae, Helicobacteraceae and Rikenellaceae decreased, while the number of Akkermansiaceae and Erysipelotrichaceae increased, suggesting that the original homeostasis of intestinal microflora was destroyed. After CH-Ⅰ treatment, the number of intestinal microflora tended to be normal, which reduced the abundance of pathogenic microbiota and increased the relative abundance of beneficial bacteria. Conclusion CH-Ⅰ can improve the composition of intestinal microflora and the behavioral function of PD mice by decreasing the abundance of pathogenic microbiota and increasing the relative abundance of beneficial bacteria.

Key words

Cerebrotein hydrolysate-Ⅰ / Parkinson’s disease / Intestinal microflora / Tyrosine hydroxylase / Immunohistochemistry / Mouse

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

YAN Kun WU Xiao-lin LIU Ying-juan GE Ke-li1 REN Lei-ming LI Hong-yun. Effect of cerebrotein hydrolysate-Ⅰon intestinal microflora regulation of mice with Parkinson’s disease[J]. Acta Anatomica Sinica. 2023, 54(5): 497-504 https://doi.org/10.16098/j.issn.0529-1356.2023.05.001

References

［1］Zhai S, Tanimura A, Graves S M, et al. Striatal synapses, circuits, and Parkinson’s disease［J］. Curr Opin Neurobiol, 2017, 48: 9-16.

［2］Wang YL, Ju B, Zhang YZ, et al. Protective effect of curcumin against oxidative stress-induced injury in rats with Parkinson’s disease through the wnt/beta-catenin signaling pathway［J］. Cell Physiol Biochem, 2017, 43(6): 2226-2241.

［3］Kowal SL, Dall TM, Chakrabarti R, et al. The current and projected economic burden of Parkinson’s disease in the United States［J］. Mov Disord, 2013, 28(3): 311-318.

［4］Mccann H, Cartwright H, Halliday GM. Neuropathology of alpha-synuclein propagation and braak hypothesis［J］. Mov Disord, 2016, 31(2): 152-160.

［5］Liu X, Liu ZhY, Chen HJ, et al. Advances in relationship between gut microbiota and Parkinson’s disease［J］. Journal of Colorectal & Anal Surgery, 2020, 26(4): 410-413. (in Chinese)

刘欣, 刘忠于, 陈晖娟, 等. 肠道菌群与帕金森病相关性的研究进展［J］. 结直肠肛门外科, 2020, 26(4): 410-413.

［6］Ma Q, Li Y, Li P, et al. Research progress in the relationship between type 2 diabetes mellitus and intestinal flora［J］. Biomed Pharmacother, 2019, 117: 109138.

［7］Yang X, Liu L, Chen J, et al. Response of intestinal bacterial flora to the long-term feeding of aflatoxin B1 (AFB1) in mice［J］. Toxins (Basel), 2017, 9(10):317.

［8］Zhao YY, Fan XL, Wang XX, et al. Research progress on intestinal microbes and central nervous system diseases［J］. Journal of Practical Traditional Chinese Internal Medicine, 2020, 34(12):64-68. (in Chinese)

赵烊烊, 范兴丽, 王晓翔,等. 肠道菌群失调与中枢神经系统性疾病研究进展［J］. 实用中医内科杂志, 2020,34(12):64-68.

［9］Fang X. Microbial treatment: the potential application for Parkinson’s disease［J］. Neurol Sci, 2019, 40(1): 51-58.

［10］Holzer P, Farzi A. Neuropeptides and the microbiota-gut-brain axis［J］. Adv Exp Med Biol, 2014, 817: 195-219.

［11］Jing XL, Huo YB, Ren LM, et al. Protective effects of cerebroprotein hydrolysate for injection (Ⅰ) on vascular dementia in rats［J］. Drug Evaluation Research, 2017, 40(7):922-925. (in Chinese)

景小龙, 侯衍豹, 任雷鸣, 等. 注射用脑蛋白水解物（Ι）对血管性痴呆大鼠的保护作用［J］. 药物评价研究，2017, 40(7):922-925.

［12］Zhou T, Zhu M, Liang Z.(-)-Epigallocatechin-3-gallate modulates peripheral immunity in the MPTP-induced mouse model of Parkinson’s disease［J］. Mol Med Rep, 2018, 17(4): 4883-4888.

［13］Caporaso JG, Lauber CL, Walters WA, et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample［J］. Proc Natl Acad Sci USA, 2011, 108(Suppl 1): 4516-4522.

［14］Chen X, Sun H, Jiang F, et al. Alteration of the gut microbiota associated with childhood obesity by 16S rRNA gene sequencing［J］. Peer J, 2020, 8:e8317.

［15］Konya T, Koster B, Maughan H, et al. Associations between bacterial communities of house dust and infant gut［J］. Environ Res, 2014, 131: 25-30.

［16］Bedarf JR, Hildebrand F, Coelho LP, et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naive Parkinson’s disease patients［J］. Genome Med, 2017, 9(1): 39. 

［17］Zhao F, Feng J, Li J, et al. Alterations of the gut microbiota in Hashimoto’s thyroiditis patients［J］. Thyroid, 2018, 28(2): 175-186.

［18］Zhao MQ, Mai YY, Lin BQ, et al. Neuroprotective effect of cerebrolysin in ophthalmology［J］. Chinese Journal of Biochemical and Pharmaceuticals, 2016, 36(12):196-199. (in Chinese)

赵明倩, 麦泳瑶, 林宝琴, 等. 脑蛋白水解物的视神经保护作用研究［J］. 中国生化药物杂志, 2016, 36(12): 196-199.

［19］Deng XJ, Huang XM, Zuo ChJ, et al. Research progress of cerebrolysin in the treatment of Alzheimer’s disease［J］. Chinese Journal of Biochemical and Pharmaceuticals, 2016, 36(11):200-204. (in Chinese)

邓湘俊, 黄夏梦, 左长京, 等. 脑蛋白水解物治疗阿尔茨海默病的研究进展［J］. 中国生化药物杂志, 2016, 36(11): 200-204.

［20］Sui R, Zang L, Bai Y. Administration of troxerutin and cerebroprotein hydrolysate injection alleviates cerebral ischemia/reperfusion injury by down-regulating caspase molecules［J］. Neuropsychiatr Dis Treat, 2019, 15: 2345-2352.

［21］Lü E, Fei XCh, Li K, et al. Effects of vasoactive intestinal peptide on synapse of MPTP-induced mice with Parkinson’s disease［J］. Acta Anatomica Sinica, 2018, 49(1):29-34. (in Chinese)

吕娥, 费学超, 李侃, 等. 血管活性肠肽对MPTP亚急性帕金森病模型小鼠突触的影响［J］. 解剖学报, 2018, 49(1): 29-34.

［22］Taylor TN, Greene JG, Miller GW. Behavioral phenotyping of mouse models of Parkinson’s disease［J］. Behav Brain Res, 2010, 211(1): 1-10.

［23］Winogrodzka A, Bergmans P, Booij J, et al. ［(123)I］β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease［J］. J Neurol Neurosurg Psychiatry, 2017, 74(3): 294-298.

［24］Becker A, Fassbender K, Oertel WH, et al. A punch in the gut-intestinal inflammation links environmental factors to neurodegeneration in Parkinson’s disease［J］. Parkinsonism Relat Disord, 2019, 60: 43-45.

［25］Zhu G, Jiang Y, Yao Y, et al. Ovotransferrin ameliorates the dysbiosis of immunomodulatory function and intestinal microbiota induced by cyclophosphamide［J］. Food Funct, 2019, 10(2): 1109-1122.